search
Back to results

Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets

Primary Purpose

Diabetes Mellitus Type 2

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Glucophage
Glucophage
Sponsored by
Merck KGaA, Darmstadt, Germany
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus Type 2 focused on measuring Diabetes, Glucophage, Metformin, sachets, tablets

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diabetes mellitus type 2 diagnosed (Baseline Glycemia > 7,0 mmol/L (126 mg/dL) or overload Glycemia > 11,0 mmol/L (198 mg/dL)
  • On treatment with metformin tablets
  • Patients with at least 2 treated co-morbidities
  • Established dose of Metformin > 1.700 mg/day
  • Age > 18 years old
  • Given informed consent

Exclusion Criteria:

  • Patients not able to take medication orally
  • According to Summary of Product Characteristics (SmPC)
  • Participating in another clinical trial 30 days prior to randomization
  • Any other illness or medical or psychiatric condition, severe and uncontrolled that could interfere in the patient's participation or in the assessment of the study results

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Glucophage sachets

    Glucophage tablets

    Arm Description

    Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.

    Patients received Glucophage tablets.

    Outcomes

    Primary Outcome Measures

    Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6

    Secondary Outcome Measures

    Objective compliance to treatment
    Objective compliance to treatment is assessed by the accountability of medication returned. Patient is assessed as compliant with an adherence of over 80%.
    Evaluation of treatment satisfaction and preferences with the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
    Rate of reported adverse events

    Full Information

    First Posted
    December 30, 2011
    Last Updated
    February 3, 2014
    Sponsor
    Merck KGaA, Darmstadt, Germany
    Collaborators
    Merck, S.L., Spain
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01510522
    Brief Title
    Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
    Official Title
    Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients, Previously Treated With Metformin Tablets
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2014
    Overall Recruitment Status
    Withdrawn
    Study Start Date
    June 2012 (undefined)
    Primary Completion Date
    June 2012 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck KGaA, Darmstadt, Germany
    Collaborators
    Merck, S.L., Spain

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is an open-label, multicenter, two-arm, parallel, randomized phase 4 study to compare the compliance in diabetes type 2 patients treated with Glucophage sachets versus patients treated with Glucophage tablets.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus Type 2
    Keywords
    Diabetes, Glucophage, Metformin, sachets, tablets

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Glucophage sachets
    Arm Type
    Experimental
    Arm Description
    Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
    Arm Title
    Glucophage tablets
    Arm Type
    Active Comparator
    Arm Description
    Patients received Glucophage tablets.
    Intervention Type
    Drug
    Intervention Name(s)
    Glucophage
    Other Intervention Name(s)
    Metformin hydrochloride
    Intervention Description
    Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
    Intervention Type
    Drug
    Intervention Name(s)
    Glucophage
    Other Intervention Name(s)
    Metformin hydrochloride
    Intervention Description
    Glucophage tablets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
    Primary Outcome Measure Information:
    Title
    Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6
    Time Frame
    Month 6
    Secondary Outcome Measure Information:
    Title
    Objective compliance to treatment
    Description
    Objective compliance to treatment is assessed by the accountability of medication returned. Patient is assessed as compliant with an adherence of over 80%.
    Time Frame
    Month 3 and month 6
    Title
    Evaluation of treatment satisfaction and preferences with the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
    Time Frame
    Baseline, month 3 and month 6
    Title
    Rate of reported adverse events
    Time Frame
    Month 3 and month 6

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diabetes mellitus type 2 diagnosed (Baseline Glycemia > 7,0 mmol/L (126 mg/dL) or overload Glycemia > 11,0 mmol/L (198 mg/dL) On treatment with metformin tablets Patients with at least 2 treated co-morbidities Established dose of Metformin > 1.700 mg/day Age > 18 years old Given informed consent Exclusion Criteria: Patients not able to take medication orally According to Summary of Product Characteristics (SmPC) Participating in another clinical trial 30 days prior to randomization Any other illness or medical or psychiatric condition, severe and uncontrolled that could interfere in the patient's participation or in the assessment of the study results
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Responsible
    Organizational Affiliation
    Merck, S.L., Spain
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets

    We'll reach out to this number within 24 hrs